Medpace Holdings, Inc. (MEDP) fair value analysis

Nasdaq · Updated 2026-09-07

Medpace Holdings, Inc. is a clinical research organization that provides drug development services to pharmaceutical, biotechnology, and medical device companies. The company operates globally, conducting clinical trials and offering related research services across multiple regions worldwide.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, MEDP is trading at a 10–25% premium to estimated fair value.

MEDP currently ranks #89 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $573.29
Sector: Healthcare
12-month range: $417.54–$594.02

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Low
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The top quarter of its range

What our data shows for MEDP

Our model validated 17 trailing price-to-earnings windows for MEDP, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $417.54–$594.02.
The 14-day relative strength index sits at a neutral 49.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for MEDP
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent MEDP news

TickrTrends' derived news-sentiment signal for MEDP is currently leaning positive, computed from recent coverage.

Medpace Stock: Cancellations Are Normalizing (NASDAQ:MEDP) (seekingalpha.com, 2026-07-25)
TickrTrends take: Medpace operates in the Healthcare sector at a valuation TickrTrends currently assesses as overvalued, making the normalization of cancellations a particularly important metric for investors monitoring whether the stock's pricing aligns with operational reality. As cancellations return to typical levels, the company's revenue predictability and client retention patterns will become clearer indicators of whether current valuation multiples are justified. Valuation-focused investors should track whether normalizing cancellations lead to margin stabilization or compression, as this will be critical to reassessing the overvalued designation.
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue? (zacks.com, 2026-07-24)
TickrTrends take: MEDP has reached its 52 week high while TickrTrends currently rates the stock as overvalued, suggesting the recent price strength may have moved valuation metrics beyond levels supported by fundamentals. For investors focused on valuation, the key question is whether the healthcare company can demonstrate earnings or revenue growth sufficient to justify its elevated price level, or whether mean reversion becomes likely. Monitoring MEDP's upcoming financial results and guidance will be critical to determining if the stock's recent momentum reflects genuine operational improvements or represents valuation risk in the Healthcare sector.
Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus (rttnews.com, 2026-07-24)
TickrTrends take: MEDP reported Q2 results according to recent market activity, which provides investors with updated financial information to assess the company's operational performance. Given TickrTrends' current overvalued designation for MEDP, valuation-focused readers should carefully examine whether the Q2 results justify the stock's current price relative to fundamental metrics in the competitive Healthcare sector. The earnings report offers an opportunity to evaluate whether MEDP's valuation multiples align with its actual earnings power and growth trajectory.

What people are saying

Follow the MEDP conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is MEDP stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), MEDP is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is MEDP's TickrTrends verdict?

MEDP's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does MEDP compare to other Healthcare stocks?

MEDP ranks #89 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is MEDP overbought or oversold?

MEDP's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

MEDP vs BIIB · MEDP vs BIO · MEDP vs BVS · MEDP vs CVS · MEDP vs INMD